

Juan C Hernandez-Boluda

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4449367/juan-c-hernandez-boluda-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150
papers

3,416
citations

33
h-index

53
g-index

162
ext. papers

4,031
ext. citations

5.3
avg, IF

4.77
L-index

#	Paper	IF	Citations
150	Second versus first wave of COVID-19 in patients with MPN.. <i>Leukemia</i> , 2022 ,	10.7	2
149	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.. <i>Leukemia Research</i> , 2022 , 115, 106821	2.7	0
148	Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT.. <i>British Journal of Haematology</i> , 2022 ,	4.5	
147	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 54	22.4	4
146	Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	1
145	Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2021 , 23, e13507	2.7	3
144	The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2040-2043	1.9	2
143	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <i>EJHaem</i> , 2021 , 2, 236-248	0.9	1
142	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1944-1952	4.4	1
141	Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2160-2172	4.4	2
140	Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. <i>Leukemia</i> , 2021 , 35, 2445-2459	10.7	3
139	Long-term follow-up of recovered MPN patients with COVID-19. <i>Blood Cancer Journal</i> , 2021 , 11, 115	7	6
138	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. <i>American Journal of Hematology</i> , 2021 , 96, 1186-1194	7.1	1
137	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
136	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021 , 35, 215-224	10.7	15
135	Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. <i>Leukemia</i> , 2021 , 35, 623-627	10.7	2
134	Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. <i>British Journal of Haematology</i> , 2021 , 192, 988-996	4.5	3

133	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021 , 96, 69-79	7.1	11
132	European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. <i>Current Research in Translational Medicine</i> , 2021 , 69, 103267	3.7	5
131	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. <i>Leukemia</i> , 2021 , 35, 485-493	10.7	45
130	Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. <i>Blood Cancer Journal</i> , 2021 , 11, 16	7	12
129	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021 , 11, 21	7	14
128	Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1593-1602	4.4	1
127	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. <i>Lancet Haematology</i> , 2021 , 8, e658-e665	14.6	4
126	CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. <i>Current Research in Translational Medicine</i> , 2021 , 69, 103304	3.7	1
125	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2147-2159	4.4	11
124	Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020 , 22, e13301	2.7	1
123	Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1347-1356	4.4	6
122	Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. <i>Leukemia Research</i> , 2020 , 91, 106338	2.7	3
121	Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. <i>Annals of Hematology</i> , 2020 , 99, 791-798	3	7
120	miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. <i>Leukemia</i> , 2020 , 34, 2648-2659	10.7	9
119	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 972-977	4.7	2
118	Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1493-1496	4.4	1
117	Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. <i>Annals of Hematology</i> , 2020 , 99, 527-537	3	7
116	Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. <i>Medicina Clínica</i> , 2020 , 155, 152-158	1	2

115	An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2020 , 209, 15-21	4	6
114	Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide. <i>Transplant Infectious Disease</i> , 2020 , 22, e13206	2.7	8
113	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 358-366	4.7	20
112	Clinical significance of <i>Pneumocystis jirovecii</i> DNA detection by real-time PCR in hematological patient respiratory specimens. <i>Journal of Infection</i> , 2020 , 80, 578-606	18.9	1
111	Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. <i>Medicina Clínica (English Edition)</i> , 2020 , 155, 152-158	0.3	1
110	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2237-2244	4.7	5
109	Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
108	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1823-1832	1.9	1
107	Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?. <i>Transplant Infectious Disease</i> , 2020 , 22, e13440	2.7	2
106	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. <i>Bone Marrow Transplantation</i> , 2020 , 55, 431-440	4.4	6
105	Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples. <i>Anticancer Research</i> , 2019 , 39, 4757-4766	2.3	3
104	Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2019 , 208, 405-414	4	1
103	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , 2019 , 78, 393-401	18.9	9
102	Spontaneously-resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes. <i>Journal of Medical Virology</i> , 2019 , 91, 1128-1135	19.7	3
101	Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. <i>Bone Marrow Transplantation</i> , 2019 , 54, 90-98	4.4	9
100	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. <i>Annals of Hematology</i> , 2019 , 98, 2319-2328	3	3
99	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. <i>Transplant Infectious Disease</i> , 2019 , 21, e13158	2.7	9
98	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2167-2171	4.7	35

97	Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. <i>Frontiers in Oncology</i> , 2019 , 9, 603	5.3	46
96	Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. <i>American Journal of Transplantation</i> , 2019 , 19, 2479-2494	8.7	13
95	Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against <i>Candida</i> spp. and <i>Aspergillus</i> spp. in Allogeneic Stem Cell Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 740-747	3.2	1
94	Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1894-1903	11.6	25
93	Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1510-1512	7	1
92	Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2019 , 98, 321-330	3	14
91	Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 94, 22-27	2.9	2
90	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1022-1030	4.7	8
89	Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?. <i>Bone Marrow Transplantation</i> , 2018 , 53, 787-790	4.4	2
88	Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2018 , 90, 1375-1382	19.7	2
87	Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Transplantation</i> , 2018 , 18, 2885-2894	8.7	17
86	Prognostic risk models for transplant decision-making in myelofibrosis. <i>Annals of Hematology</i> , 2018 , 97, 813-820	3	5
85	Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigational Approach. <i>Clinical Infectious Diseases</i> , 2018 , 67, 805-807	11.6	10
84	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018 , 8, 25	7	18
83	Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. <i>British Journal of Haematology</i> , 2018 , 181, 397-400	4.5	18
82	Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin. <i>Experimental and Molecular Pathology</i> , 2018 , 105, 139-143	4.4	1
81	Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , 2018 , 90, 1438-1443	19.7	7
80	Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Medical Microbiology</i> , 2018 , 67, 814-819	3.2	2

79	Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 563-570	4.7	24
78	Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison. <i>Mycoses</i> , 2018 , 61, 206-212	5.2	11
77	Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. <i>Blood Cancer Journal</i> , 2018 , 8, 91	7	24
76	Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. <i>Transplant Infectious Disease</i> , 2018 , 20, e12926	2.7	16
75	Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. <i>Haematologica</i> , 2017 , 102, 103-109	6.6	33
74	Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. <i>Neurological Sciences</i> , 2017 , 38, 1213-1221	3.5	26
73	A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1177-1185	4.7	17
72	Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2017 , 19, e12717	2.7	15
71	A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study. <i>Transplant Infectious Disease</i> , 2017 , 19, e12729	2.7	12
70	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2017 , 178, 764-771	4.5	19
69	When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1448-1451	4.4	3
68	Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. <i>European Journal of Haematology</i> , 2017 , 98, 407-414	3.8	13
67	A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. <i>PLoS ONE</i> , 2017 , 12, e0173532	3.7	4
66	Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. <i>Journal of Health Economics and Outcomes Research</i> , 2017 , 5, 162-174	1.6	1
65	Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant. <i>Transplant Infectious Disease</i> , 2016 , 18, 89-92	2.7	6
64	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , 2016 , 101, 926-31	6.6	91
63	Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. <i>Blood Cancer Journal</i> , 2016 , 6, e493	7	55
62	Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. <i>British Journal of Haematology</i> , 2016 , 172, 786-93	4.5	41

61	Alleviating anemia and thrombocytopenia in myelofibrosis patients. <i>Expert Review of Hematology</i> , 2016 , 9, 489-96	2.8	8
60	Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method. <i>Annals of Hematology</i> , 2016 , 95, 719-32	3	3
59	Long-term results of prednisone treatment for the anemia of myelofibrosis. <i>Leukemia and Lymphoma</i> , 2016 , 57, 120-4	1.9	12
58	Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2016 , 96, 285-90	3.8	12
57	High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. <i>Leukemia</i> , 2016 , 30, 2032-2038	10.7	55
56	Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. <i>Annals of Hematology</i> , 2015 , 94, 1791-6	3	37
55	Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. <i>Annals of Hematology</i> , 2015 , 94, 911-8	3	40
54	BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia. <i>Leukemia Research</i> , 2015 , 39, 1278-1278	2.7	5
53	Target hematologic values in the management of essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2015 , 94, 4-11	3.8	14
52	JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. <i>American Journal of Hematology</i> , 2014 , 89, 517-23	7.1	29
51	BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. <i>Cancer Cell</i> , 2014 , 26, 428-442	24.3	233
50	Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. <i>Annals of Hematology</i> , 2014 , 93, 2037-43	3	46
49	The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. <i>Haematologica</i> , 2014 , 99, e55-7	6.6	42
48	Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain. <i>Journal of Medical Economics</i> , 2014 , 17, 435-41	2.4	6
47	Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. <i>Annals of Hematology</i> , 2013 , 92, 771-5	3	21
46	Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. <i>British Journal of Haematology</i> , 2013 , 161, 865-71	4.5	23
45	A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2013 , 88, 883-9	7.1	5
44	Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , 2012 , 36, 174-81	2.7	17

43	Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML). <i>Leukemia Research</i> , 2012 , 36, e50-1	2.7	
42	A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2012 , 119, 5221-8	2.2	35
41	Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. <i>Blood</i> , 2012 , 119, 1363-9	2.2	156
40	Polymyositis after donor lymphocyte infusion. <i>International Journal of Hematology</i> , 2012 , 96, 386-9	2.3	9
39	Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. <i>British Journal of Haematology</i> , 2011 , 152, 81-8	4.5	55
38	An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1249-54	1.9	5
37	Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , 2011 , 35, 1014-9	2.7	44
36	Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absence of clinically suspected infection. <i>Bone Marrow Transplantation</i> , 2011 , 46, 1484-6	4.4	8
35	Reconstitution of CMV pp65 and IE-1-specific IFN- γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2011 , 46, 1437-43	4.4	54
34	Prognostic Factors in Classic Myeloproliferative Neoplasms 2011 , 85-96		
33	Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFN γ CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2010 , 45, 543-9	4.4	49
32	An assessment of the effect of human herpesvirus-6 replication on active cytomegalovirus infection after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 653-61	4.7	30
31	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. <i>Haematologica</i> , 2010 , 95, 1317-24	6.6	41
30	Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. <i>Blood</i> , 2010 , 116, 1205-10; quiz 1387	2.2	175
29	XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2010 , 85, 482-6	7.1	23
28	Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFN γ CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection. <i>Journal of Medical Virology</i> , 2010 , 82, 1208-15	19.7	28
27	Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia. <i>Leukemia Research</i> , 2009 , 33, 589-92	2.7	3
26	Prognostic factors in chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2009 , 22, 343-53	4.2	14

25	Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 3311-8	9.7	96
24	Enumeration of cytomegalovirus-specific interferongamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. <i>Haematologica</i> , 2008 , 93, 1434-6	6.6	39
23	Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. <i>Leukemia</i> , 2007 , 21, 143-50	10.7	150
22	Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. <i>Leukemia</i> , 2007 , 21, 1218-23	10.7	97
21	JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. <i>Haematologica</i> , 2007 , 92, 1717-8	6.6	44
20	Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2006 , 134, 184-6	4.5	63
19	Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. <i>Bone Marrow Transplantation</i> , 2005 , 36, 847-53	4.4	43
18	Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. <i>Leukemia and Lymphoma</i> , 2005 , 46, 717-22	1.9	25
17	Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. <i>British Journal of Haematology</i> , 2004 , 127, 399-403	4.5	111
16	Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. <i>Experimental Hematology</i> , 2003 , 31, 204-10	3.1	35
15	Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2003 , 120, 500-4	4.5	5
14	Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. <i>Haematologica</i> , 2003 , 88, 1117-22	6.6	22
13	Idiopathic myelofibrosis associated with primary biliary cirrhosis. <i>Leukemia and Lymphoma</i> , 2002 , 43, 673-4	1.9	9
12	Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies. <i>Drugs of Today</i> , 2002 , 38, 601-13		25
11	Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells?. <i>Blood</i> , 2001 , 98, 2352-7	2.2	66
10	Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia. <i>Annals of Hematology</i> , 2001 , 80, 516-20	3	6
9	Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. <i>European Journal of Haematology</i> , 2001 , 66, 324-7	3.8	19
8	Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. <i>European Journal of Haematology</i> , 2000 , 65, 104-8	3.8	25

7	Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature. <i>Leukemia and Lymphoma</i> , 2000 , 38, 83-90	1.9	20
6	Non-HodgkinB lymphoma following untreated essential thrombocythemia. <i>Leukemia and Lymphoma</i> , 2000 , 36, 421-3	1.9	6
5	Danazol treatment of idiopathic myelofibrosis with severe anemia. <i>Haematologica</i> , 2000 , 85, 595-9	6.6	47
4	Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. <i>Leukemia</i> , 1999 , 13, 150-4	10.7	179
3	Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience. <i>Haematologica</i> , 1999 , 84, 26-31	6.6	9
2	Treatment of elderly patients with AML: results of an individualized approach. <i>Haematologica</i> , 1998 , 83, 34-9	6.6	6
1	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR / CMWP of EBMT analysis. <i>British Journal of Haematology</i> ,	4.5	